Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Link opens in a new tab
Search content at Icahn School of Medicine at Mount Sinai
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Challenges in IBD Research: Precision Medicine
Lee A. Denson
, Mark Curran
, Dermot P.B. McGovern
, Walter A. Koltun
, Richard H. Duerr
, Sandra C. Kim
, R. Balfour Sartor
, Francisco A. Sylvester
, Clara Abraham
, Edwin F. de Zoeten
, Corey A. Siegel
, Richéal M. Burns
, Angela M. Dobes
, Nataly Shtraizent
, Gerard Honig
, Caren A. Heller
, Andrés Hurtado-Lorenzo
, Judy H. Cho
Research output
:
Contribution to journal
›
Review article
›
peer-review
79
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Challenges in IBD Research: Precision Medicine'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Inflammatory Bowel Disease
100%
Precision Medicine
100%
Disease Research
100%
Research Precision
100%
Disease Course
40%
Molecular Technology
40%
Main Gap
40%
Treatment Response
20%
Clinical Characteristics
20%
Systems Biology
20%
Natural History
20%
Valuable Resources
20%
Disease Treatment
20%
Disease Activity
20%
Improved Patient Outcomes
20%
Clinical Analysis
20%
Disease Susceptibility
20%
Longitudinal Cohort Study
20%
Environmental Triggers
20%
Treatment Monitoring
20%
Machine Learning Approach
20%
Predicting Diseases
20%
Clinical Utility
20%
Disease Behavior
20%
Disease Mechanisms
20%
Biological Characteristics
20%
Cost-effective Care
20%
Patient Costs
20%
Standardized Method
20%
Disease Prediction
20%
Pragmatic Clinical Trial
20%
Gap Current
20%
Prospective Longitudinal Cohort
20%
Technology System
20%
Gap Area
20%
Patient-centered Research
20%
Human Inflammatory Bowel Disease
20%
Research Prioritization
20%
Multi-omics Data Integration
20%
Treatment Response Prediction
20%
Biology Learning
20%
Precision Biomarkers
20%
Clinical Data Integration
20%
Medicine and Dentistry
Personalized Medicine
100%
Inflammatory Bowel Disease
100%
Biological Marker
50%
Treatment Response
33%
Disease Course
33%
Health Care Cost
16%
Clinician
16%
Disease Predisposition
16%
Prognostication
16%
Combination Therapy
16%
Clinical Research
16%
Cohort Studies
16%
Multi-Omics
16%